Peroxisomal fatty acid beta-oxidation in HepG2 cells

Human hepatoblastoma-derived cell lines are often used to model liver-specific functions. While peroxisomal fatty acid beta-oxidation is well-documented in liver tissue, its activity in cultured cells remains less certain. Prior studies have shown that peroxisomes and mitochondria handle different fatty acid chains, but the extent of peroxisomal involvement in HepG2 cells was unclear. Researchers have already established that peroxisomes contain specific enzymes for beta-oxidation, but the presence of these enzymes in HepG2 cells had not been confirmed. This gap motivated a closer examination of HepG2 peroxisomal function. No prior work had resolved whether these cells could serve as a model for peroxisomal metabolism. The need for a reliable in vitro model is critical for studying fatty acid oxidation. This uncertainty drove the current investigation into HepG2 peroxisomal activity. Understanding this could aid in modeling human metabolic disorders.

This study aimed to assess whether HepG2 cells could serve as a model for peroxisomal fatty acid beta-oxidation. Researchers focused on the ability of these cells to process very-long-chain fatty acids (VLCFA), a key function of peroxisomes. The specific problem addressed was the lack of evidence confirming peroxisomal activity in HepG2 cells. The motivation stemmed from the need for a reliable cell line to study human peroxisomal metabolism. By isolating peroxisomes from mitochondria, the team could directly measure beta-oxidation. The study also aimed to compare HepG2 activity with human liver homogenates. Researchers wanted to determine if HepG2 peroxisomes contained the necessary enzymes. This work could clarify the utility of HepG2 cells in metabolic research.

The researchers used density gradient centrifugation to isolate peroxisomes from HepG2 cells. They compared these organelles to mitochondria and other subcellular fractions. Homogenates and digitonin-treated cells were used to measure fatty acid oxidation rates. Long-chain and very-long-chain fatty acids were tested as substrates. The team assessed the effect of inhibitors like antimycin A and rotenone on oxidation. Carnitine dependence was evaluated by measuring oxidation in its presence and absence. Immunoreactive acyl-CoA oxidase was detected using antibody-based assays. The presence of VLCFA-CoA synthetase activity was also confirmed.

HepG2 cells oxidized both long-chain and very-long-chain fatty acids. Peroxisomal beta-oxidation occurred independently of carnitine. Antimycin A and rotenone had no effect on peroxisomal oxidation. Carnitine palmitoyl transferase I inhibition did not block the process. HepG2 peroxisomes contained acyl-CoA oxidase, a key peroxisomal enzyme. VLCFA-CoA synthetase activity was detected in peroxisomes. Oxidation rates were lower than in human liver homogenates. These findings suggest HepG2 cells support peroxisomal fatty acid metabolism.

The authors suggest that HepG2 cells may serve as a model for peroxisomal fatty acid beta-oxidation. The presence of acyl-CoA oxidase and VLCFA-CoA synthetase supports this claim. Peroxisomal activity was confirmed through inhibitor resistance and enzyme detection. The study did not propose new drug targets or future directions. The findings do not imply that HepG2 cells fully replicate liver peroxisomal function. The results do not suggest that these cells are superior to other models. The authors did not claim that HepG2 cells are essential for all peroxisomal studies. The implications are limited to the use of HepG2 cells in peroxisomal metabolism research.